News | April 12, 2012

FDA Panel Recommends Approval for Automated Breast Ultrasound for Women with Dense Breasts

April 12, 2012 — U-Systems announced that the U.S. Food and Drug Administration’s (FDA) Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system. U-Systems’ premarket approval (PMA) application is seeking a breast cancer screening indication for the somo•v ABUS system, which is currently FDA-cleared for diagnostic use as an adjunct to mammography.

If final PMA approval is granted, the somo•v ABUS system would be the only ultrasound device in the United States approved for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue. Although the FDA is not bound by the recommendations of its advisory committees, it generally follows their advice.

“With the positive FDA panel review of the somo•v for breast cancer screening, we now have the opportunity to integrate 3-D automated breast ultrasound screening into clinical practice, which will enable us to find previously undetectable cancers,” said Rachel Brem, M.D., director of breast imaging at The George Washington University Hospital, Washington, D.C. “Mammography is an effective tool at finding breast cancer, but it doesn’t work equally well in everyone. In women with dense breasts, we can’t see over a third of breast cancers, so we need other technologies, other approaches.

“The potential of 3-D ABUS in a screening environment is to find these 30 percent additional cancers that would not have been found with what is now the standard of care,” Brem added.

Dense breast tissue not only increases the risk of breast cancer up to four to six times but also makes cancer more difficult to detect via mammography, according to multiple large studies. One study, published in the New England Journal of Medicine, showed 35 percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks appearance of tumors (Boyd, et al, NEJM 2007:356:227-36M). As breast density goes up, the accuracy of the mammogram goes down.

“We are very excited the FDA Panel recommended approval of a breast cancer screening indication for the somo•v ABUS system,” said Ron Ho, president and CEO of U-Systems. “If the FDA approves the somo•v PMA, this important adjunctive screening tool for women with dense breasts has the opportunity to become widely available in clinical practice. This is vitally important, because at least 40% of women in the U.S. have dense breast tissue.”

Using proprietary technology to automate the ultrasound imaging process, the somo•v ABUS system was developed specifically for the high-volume, breast cancer screening environment. The somo•VIEWer advanced 3-D workstation enables fast, accurate review and archive of patient exams, optimizing breast ultrasound screening workflow.

For more information: www.u-systems.com

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overweight Women May Need More Frequent Mammograms
News | Mammography | January 04, 2018
Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become...
About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

Feature | Breast Imaging | January 02, 2018 | Kathryn Pearson Peyton, M.D.
Sixty million women undergo regular screening mammography in the United States, but even in the digital age, it is di
Double Black Announces Gemini Series Monitors for Multimodality and Digital Breast Imaging
Technology | Flat Panel Displays | December 28, 2017
December 28, 2017 — Double Black Imaging and their Image Systems Division are releasing their Gemini Series 6MP and 8
iCAD's PowerLook Tomo Detection Experiences Growing Adoption
News | Mammography | December 14, 2017
December 14, 2017 — iCAD Inc.
Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Breast Cancer Screening Performance Impacted by Mean Mammographic Compression Pressure
News | Mammography | December 08, 2017
Dutch researchers demonstrated a strong relationship between compression pressure in mammography and breast cancer...
Videos | Mammography | December 06, 2017
Martin Yaffe, Ph.D., FAAPM, senior scientist, physical sciences/imaging research, Sunnybrook Health Sciences Centre,
Overlay Init